sodium glucose co-transport inhibitor
Showing 1 - 25 of >10,000
Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)
Completed
- Healthy Volunteers
- Placebo
- Canagliflozin
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)
Not yet recruiting
- Atrial Fibrillation
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Rhythm control and anticoagulation
- (no location specified)
Aug 14, 2023
Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)
Recruiting
- Heart Failure
- Reduced Ejection Fraction Heart Failure
- Empagliflozin 10 MG
- Dapagliflozin 10 MG
-
Damanhūr, Elbehairah, EgyptDamanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023
Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))
Not yet recruiting
- Metabolic Associated Fatty Liver Disease
- dapagliflozin (Forxiga)
- (no location specified)
Mar 13, 2023
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,
Not yet recruiting
- Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
- (no location specified)
Jan 22, 2023
Cardiorenal Syndrome Trial in New Haven (Dapagliflozin)
Not yet recruiting
- Cardiorenal Syndrome
-
New Haven, ConnecticutYale New Haven Hospital
Oct 26, 2023
Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- SGLT2 inhibitor
- Glimepiride
-
Seoul, Korea, Republic ofYonsei University College of Medicine
Aug 1, 2023
Chronic Kidney Disease, Diabetes, Type 2, Hypertension Trial in Genova (Dapagliflozin 10mg Tab, Placebo)
Recruiting
- Chronic Kidney Disease
- +2 more
- Dapagliflozin 10mg Tab
- Placebo
-
Genova, GE, ItalyIRCCS Ospedale Policlinico San Martino
Aug 10, 2023
Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)
Not yet recruiting
- Aortic Valve Stenosis
- Myocardium biopsy
-
Strasbourg, FranceHôpitaux Universitaires de Strasbourg
Apr 13, 2023
Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral
Not yet recruiting
- Acute Kidney Injury
- +2 more
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Placebo
-
Amsterdam, Netherlands
- +5 more
Oct 18, 2022
Lung Adenocarcinoma Trial in Los Angeles (drug, procedure, other)
Recruiting
- Lung Adenocarcinoma
-
Los Angeles, CaliforniaYesenia Calzada
Jan 27, 2023
MDD Trial in New York (Empagliflozin)
Not yet recruiting
- Major Depressive Disorder
-
New York, New YorkNYU Langone Health
Feb 24, 2023
(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in
Not yet recruiting
- Diabetes Mellitus, Type 2
- Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
- (no location specified)
May 22, 2023
Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim International GmbH
Aug 19, 2022
Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)
Not yet recruiting
- Kidney Transplant Recipients
- Dapagliflozin 10 MG
- Semaglutide, 1.0 mg/mL
-
Toronto, Ontario, CanadaToronto General Hospital
Jul 6, 2023
Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular
Not yet recruiting
- SGLT2 Inhibitiors Remodeling Effect
- Chronic Heart Disease
- Sodium-glucose cotransporter 2 inhibitor
- (no location specified)
Nov 14, 2023
Cystinuria Trial in San Francisco (Dapagliflozin)
Not yet recruiting
- Cystinuria
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 13, 2022
Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan
Recruiting
- Heart Failure
- +2 more
- SGLT2 inhibitor
-
Roma, RM, ItalyFondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023
Tricuspid Regurgitation Trial in Seoul (Dapagliflozin Propanediol Hydrate 12.3 mg)
Recruiting
- Tricuspid Regurgitation
- Dapagliflozin Propanediol Hydrate 12.3 mg
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 9, 2023
SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac
Recruiting
- Coronary Artery Disease
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
-
Shah Alam, Selangor, MalaysiaInstitute for Clinical Research, National Institutes of Health,
Nov 9, 2023
Myocardial Ischemia Trial (Dapagliflozin 10mg Tab, Placebo)
Not yet recruiting
- Myocardial Ischemia
- Dapagliflozin 10mg Tab
- Placebo
- (no location specified)
Feb 27, 2023
Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)
Recruiting
- Heart Attack
- Enlarged Heart
- Dapagliflozin
- Placebo
-
Minneapolis, MinnesotaMinneapolis Heart Institute Foundation
Aug 4, 2022
Diabetic Nephropathy Type 2 Trial (Empagliflozin 25 MG, Enalapril Maleate 20 mg)
Not yet recruiting
- Diabetic Nephropathy Type 2
- Empagliflozin 25 MG
- Enalapril Maleate 20 mg
- (no location specified)
May 9, 2022
Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)
Recruiting
- Heart Failure With Reduced Ejection Fraction
- SGLT2i
- No SGLT2i
-
Chicago, IllinoisUniversity of Chicago
Nov 11, 2022
SGLT2 Inhibition in Heart Failure
Recruiting
- Heart Failure
- Sodium-glucose cotransporter 2 inhibitor
-
Belfast, United KingdomBelfast Health and Social Care Trust
Nov 15, 2023